Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK).

Full DD Report for MACK

You must become a subscriber to view this report.


Recent News from (NASDAQ: MACK)

Merrimack Pharmaceuticals (MACK) Presents at Baird's Global Healthcare Conference - Slideshow
The following slide deck was published by Merrimack Pharmaceuticals in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 07 2018 14:09
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
CAMBRIDGE, Mass. , Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evalua...
Source: PR Newswire
Date: September, 06 2018 06:50
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX - New Research Emphasizes Economic Growth
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion Corporation (NASDAQ:CLSN), Alpha and Omega Semiconductor Limited ...
Source: GlobeNewswire
Date: August, 16 2018 08:00
Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q2 2018 Results - Earnings Call Transcript
Merrimack Pharmaceuticals (MACK) Q2 2018 Earnings Conference Call August 7, 2018 8:30 AM ET Executives Geoff Grande - Senior Director, Communications Richard Peters - President and Chief Executive Officer Jean Franchi - Chief Financial Officer Analysts Marc Frahm - Cowen &a...
Source: SeekingAlpha
Date: August, 07 2018 12:33
Merrimack Reports Second Quarter 2018 Financial Results
CAMBRIDGE, Mass. , Aug. 7, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its second quarter 2018 financial results for the period ended June 30, 2018 . "A cornerstone of...
Source: PR Newswire
Date: August, 07 2018 06:30
Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call
CAMBRIDGE, Mass. , July 31, 2018 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, August 7, 2018.   The call will p...
Source: PR Newswire
Date: July, 31 2018 16:10
Merrimack Secures $25 Million Debt Facility with Hercules Capital
CAMBRIDGE, Mass. , July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (NYSE: HTGC), $15 million of w...
Source: PR Newswire
Date: July, 02 2018 16:15
Merrimack Fails Phase 2 Pancreatic Cancer Study, But Opportunity Remains
Recently, Merrimack Pharmaceuticals ( MACK ) announced that it had failed its phase 2 pancreatic cancer study . It has chosen to end this clinical program using the drug MM-141 (istiratumab). I feel that this study was a long-shot at best, and should not have caused the selloff that it di...
Source: SeekingAlpha
Date: June, 26 2018 14:34
Midday Gainers / Losers (06/25/2018)
Gainers : XRM +100% . XBIO +96% . YECO +69% . ABIL +66% . TSRI +33% . LGCYO +32% . ATV +31% . CADC +20% . LGCYP +18% . VLRX +17% . More news on: Xerium Technologies, Inc., Xenetic Biosciences, Inc., Yulong Eco-Materials, Stocks on the move, , Read more ....
Source: SeekingAlpha
Date: June, 25 2018 12:41
Premarket Losers as of 9:05 am (06/25/2018)
SPHS   -46%  after halting trial on patient death. More news on: Sophiris Bio, Merrimack Pharmaceuticals, TransEnterix, Inc., Stocks on the move, Read more ...
Source: SeekingAlpha
Date: June, 25 2018 09:13

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-134.114.044.15733.9939,342
2018-12-124.124.114.234.0551,367
2018-12-114.274.124.354.1136,936
2018-12-104.2514.254.334.1725,827
2018-12-074.194.234.264.1551,131

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-134,98115,68231.7625Cover
2018-12-129,12520,35744.8249Short
2018-12-115,92811,99049.4412Short
2018-12-1060110,9395.4941Cover
2018-12-071,6067,93820.2318Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MACK.


About Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

Logo for Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: MACK)

      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 27 2018
      Proxy soliciting materials. Revised preliminary material
      Filing Type: PRER14AFiling Source: edgar
      Filing Date: April, 26 2018
      Preliminary proxy statement providing notification matters to be brought to a vote
      Filing Type: PRE 14AFiling Source: edgar
      Filing Date: April, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: MACK)

      Daily Technical Chart for (NASDAQ: MACK)


      Stay tuned for daily updates and more on (NASDAQ: MACK)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: MACK)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MACK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MACK and does not buy, sell, or trade any shares of MACK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/